Senior Scientist, Neuroscience Program
Ottawa Hospital Research Institute
Professor of Medicine, Neurology
University of Ottawa
Director, Multiple Sclerosis Research Unit, Neurology
Ottawa Hospital-General Campus
- Neuroimmunology as applied to the study of MS
- Clinical MS research
- Therapeutic trials in MS
Dr. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus and a Senior Scientist at the Ottawa Hospital Research Institute. A graduate of the University of Toronto, Dr. Freedman holds his Masters Degree in Molecular Neurochemistry and continued his postgraduate work specializing in neurology and neuroimmunology. His specialized training took him to the Weizmann Institute of Science, Israel; The National Hospital, Queen Square, London UK, as well as the Montreal Neurological Institute, where he subsequently was an Assistant Professor. He holds his specialist certification in Quebec CSPQ and all of Canada FRCP(C) and is a Fellow of both the American Neurological Association (FANA) and the American Academy of Neurology (FAAN).
Dr. Freedman has published over 250 pieces, including articles, books, book chapters and abstracts and has been invited to give hundreds of lectures and presentations nationally and internationally. His extensive research includes the area of molecular neurochemistry, cellular immunology, neuroimmunology and clinical studies in MS. He is currently holding peer reviewed and industry related funding for translational research investigating immune mechanisms of damage in multiple sclerosis, with particular interest in the role of gamma-delta T-cells. He is also the lead investigator in the Canadian Bone Marrow Transplant Study in MS and co-chair of the International Mesenchymal Stem Cell Transplantation Study Group.
Dr. Freedman has over 25 years of experience in the management of patients with multiple sclerosis and has been the principal investigator on numerous clinical trials with new therapeutic agents for MS. He has experience from serving on several research study steering committees as well as data safety monitoring boards. He serves on the editorial boards for several journals including the Multiple Sclerosis Journal. He has also served on several national and international committees and is currently the Treasurer of the Americas Committee for Treatment and Research in MS (ACTRIMS).
, Thompson EJ, Deisenhammer F, Giovannoni F, Grimsley G, Keir G, Ohman S, Racke MK, Sharief M, Sindic CJM. Special Report: Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A Consensus Statement. Arch Neurol. 2005 June;62(6):865-70.
Chen JT, Collins DL, Freedman, MS
, Atkins HL,and Arnold DL, the Canadian MS/BMT Study Group, Arnold DL. Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. NeuroImage. 2005 May 1;25(4):1272-1278.
, Francis GS, Sanders EACM, Rice GPA, O'Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard J-P, Abramsky O, Pelletier J, O'Brien F, for the OWIMS Study Group and UBC MS/MRI Research Group. Randomized study of one-weekly interferon -1a therapy in relapsing multiple sclerosis: Three year data from the OWIMS Study. Multiple Scler. 2005;11:41-45.
McFarland H, Barkhof F, Calabresi P, Clanet M, Cohen J, Cutter G, Freedman MS
, Lublin F, Metz L, Miller A, Montalban X, Noseworthy J, O'Connor P, Panitch H, Petkau J, Polman C, Reingold S, Schwid S, Thompson A, Wolinsky J. On behalf of the National MS Society Advisory Committee on Clinical Trials of New Agents in MS. The future of MS therapies: redesigning MS clinical trials in a new therapeutic era. Multiple Scler. 2005;11:669-676.
. Defining the standards of multiple sclerosis research. Clinical Trends in Neurology. 1:20-24. June 2005.